In a significant consolidation within the mRNA therapeutics space, BioNTech has agreed to acquire its rival CureVac through an all-stock transaction valued at $1.25 billion, a move that comes just weeks before the companies were set to face off in German court over patent disputes.
The agreement, announced Thursday, will see CureVac shareholders receive approximately $5.46 worth of BioNTech’s U.S.-listed shares for each CureVac share they hold. Following the completion of the merger, CureVac stockholders will control between 4% and 6% of BioNTech.
The acquisition appears strategically timed, as it precedes a scheduled July 1 trial in Dusseldorf where the companies were due to battle over patent infringement claims. CureVac had alleged that BioNTech violated four of its patents, with the European Patent Office having already upheld two of them. A separate U.S. trial was also looming, scheduled for September 8 in Virginia.
Financial analysts suggest that avoiding potential courtroom losses may have been a key driver behind BioNTech’s decision. According to Evercore ISI analyst Umer Raffat, BioNTech could have faced up to $3 billion in royalty payments had CureVac prevailed in the patent litigation. The acquisition price tag, therefore, represents a potentially significant cost saving compared to a possible adverse court ruling.
The two companies share a complex history in the mRNA field. During the early stages of the COVID-19 pandemic, both were racing to develop coronavirus vaccines. While BioNTech, through its partnership with Pfizer, successfully created the first approved COVID-19 vaccine, CureVac’s attempt failed to meet efficacy requirements and was ultimately abandoned.
Beyond resolving legal tensions, the merger aligns with BioNTech’s oncology ambitions. Both companies have made cancer research a priority, with CureVac’s portfolio including early-stage cancer vaccines. Notable among these is a brain cancer vaccine that has produced initial clinical data and a lung cancer immunotherapy recently approved for human trials.
However, Leerink Partners analyst Mani Foroohar notes that CureVac’s early-stage oncology pipeline required a development partner to effectively compete in personalized cancer vaccines, a field where BioNTech has established expertise. Meanwhile, Raffat suggests that the deal terms indicate minimal value was assigned to CureVac’s development pipeline.
The acquisition marks a significant shift for CureVac, which had previously pivoted its focus after selling most of its influenza and COVID-19 vaccine rights to GSK to concentrate on cancer research. The company had generated considerable attention early in the pandemic, even sparking unconfirmed rumors of potential U.S. government interest in acquiring its research.
This consolidation represents a major development in the mRNA therapeutics landscape, combining two pioneering companies in the field. While the immediate benefit appears to be the resolution of costly patent disputes, the merger could potentially accelerate the development of mRNA-based cancer treatments through the combination of both companies’ technological expertise and research capabilities.
The transaction, occurring against the backdrop of evolving mRNA technology applications beyond vaccines, suggests a strategic positioning for future therapeutic developments, particularly in oncology. However, the relatively modest valuation indicates that the immediate priority may have been resolving the patent dispute rather than acquiring CureVac’s development pipeline.
Be First to Comment